Katherine Dawson

4.9k total citations · 2 hit papers
32 papers, 3.5k citations indexed

About

Katherine Dawson is a scholar working on Pathology and Forensic Medicine, Oncology and Rheumatology. According to data from OpenAlex, Katherine Dawson has authored 32 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pathology and Forensic Medicine, 11 papers in Oncology and 7 papers in Rheumatology. Recurrent topics in Katherine Dawson's work include Multiple Sclerosis Research Studies (18 papers), Polyomavirus and related diseases (6 papers) and Rheumatoid Arthritis Research and Therapies (6 papers). Katherine Dawson is often cited by papers focused on Multiple Sclerosis Research Studies (18 papers), Polyomavirus and related diseases (6 papers) and Rheumatoid Arthritis Research and Therapies (6 papers). Katherine Dawson collaborates with scholars based in United States, United Kingdom and Germany. Katherine Dawson's co-authors include Minhua Yang, Marianne T. Sweetser, Ralf Gold, Ludwig Kappos, Sarah Sheikh, Krzysztof Selmaj, Douglas L. Arnold, Amit Bar‐Or, Eva Havrdová and Robert J. Fox and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Katherine Dawson

30 papers receiving 3.4k citations

Hit Papers

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relaps... 2012 2026 2016 2021 2012 2012 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
    2012 1.3k citations Ralf Gold, Ludwig Kappos et al. New England Journal of Medicine profile →
  2. Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
    2012 1.0k citations Robert J. Fox, David H. Miller et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Katherine Dawson United States 18 2.3k 903 806 762 656 32 3.5k
Gavin Giovannoni United Kingdom 10 3.5k 1.5× 735 0.8× 1.4k 1.8× 1.2k 1.5× 878 1.3× 20 4.6k
P Burtin France 16 1.6k 0.7× 1.8k 1.9× 443 0.5× 525 0.7× 350 0.5× 40 4.0k
Sarah Ryan United States 15 559 0.2× 1.5k 1.7× 644 0.8× 176 0.2× 158 0.2× 21 2.8k
Roberto Piva Italy 41 1.2k 0.5× 2.3k 2.5× 1.5k 1.9× 551 0.7× 44 0.1× 113 4.9k
Serena Ruggieri Italy 23 815 0.4× 341 0.4× 241 0.3× 266 0.3× 168 0.3× 75 1.6k
Chuanzhen Lü China 31 561 0.2× 679 0.8× 166 0.2× 899 1.2× 181 0.3× 87 2.5k
Matthew D. Linnik United States 26 249 0.1× 1.4k 1.5× 271 0.3× 268 0.4× 1.2k 1.8× 61 3.6k
Daniel D. Buchanan Australia 45 3.1k 1.3× 2.0k 2.2× 3.0k 3.8× 371 0.5× 61 0.1× 181 6.2k
Yasuyuki Kihara Japan 30 332 0.1× 1.9k 2.1× 448 0.6× 104 0.1× 417 0.6× 89 3.6k
René Santer Germany 36 305 0.1× 2.3k 2.6× 204 0.3× 122 0.2× 925 1.4× 145 5.1k

Countries citing papers authored by Katherine Dawson

Since Specialization
Citations

This map shows the geographic impact of Katherine Dawson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katherine Dawson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katherine Dawson more than expected).

Fields of papers citing papers by Katherine Dawson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katherine Dawson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katherine Dawson. The network helps show where Katherine Dawson may publish in the future.

Co-authorship network of co-authors of Katherine Dawson

This figure shows the co-authorship network connecting the top 25 collaborators of Katherine Dawson. A scholar is included among the top collaborators of Katherine Dawson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katherine Dawson. Katherine Dawson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Murray, Katherine T., et al.. (2024). Disrupting Academia’s Care-Free Narrative. SHILAP Revista de lepidopterología. 11(3). 175–192. 1 indexed citations
2.
Faber, Catharina G., Nadine Attal, Giuseppe Lauria, et al.. (2023). Efficacy and safety of vixotrigine in idiopathic or diabetes-associated painful small fibre neuropathy (CONVEY): a phase 2 placebo-controlled enriched-enrolment randomised withdrawal study. EClinicalMedicine. 59. 101971–101971. 13 indexed citations
3.
Dawson, Katherine. (2023). A share in the sands: trips, pits and potholes in Accra, Ghana. Africa. 93(1). 40–59. 7 indexed citations
4.
5.
Arnold, Douglas L., Ralf Gold, Ludwig Kappos, et al.. (2014). Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. Journal of Neurology. 261(12). 2429–2437. 37 indexed citations
6.
7.
Dawson, Katherine, et al.. (2013). The time course of blur adaptation in emmetropes and myopes. Ophthalmic and Physiological Optics. 33(3). 305–310. 31 indexed citations
8.
Sheikh, Sarah, Ivan Nestorov, John O’Gorman, et al.. (2013). Tolerability and Pharmacokinetics of Delayed-Release Dimethyl Fumarate Administered With and Without Aspirin in Healthy Volunteers. Clinical Therapeutics. 35(10). 1582–1594.e9. 48 indexed citations
9.
Havrdová, Eva, Michael Hutchinson, Nuwan Kurukulasuriya, et al.. (2013). Oral BG-12 (dimethyl fumarate) for relapsing–remitting multiple sclerosis: a review of DEFINE and CONFIRM. Expert Opinion on Pharmacotherapy. 14(15). 2145–2156. 34 indexed citations
10.
11.
Bar‐Or, Amit, Ralf Gold, Ludwig Kappos, et al.. (2013). Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the DEFINE study. Journal of Neurology. 260(9). 2297–2305. 59 indexed citations
12.
13.
Hutchinson, Michael, Robert J. Fox, David H. Miller, et al.. (2013). Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the CONFIRM study. Journal of Neurology. 260(9). 2286–2296. 74 indexed citations
14.
15.
Havrdová, Eva, Ralf Gold, Robert J. Fox, et al.. (2012). PND3 Relapses Requiring Intravenous Steroids and Multiple Sclerosis-Related Hospitalizations: Findings From the Phase 3 Define and Confirm Studies. Value in Health. 15(7). A546–A546. 2 indexed citations
16.
Gold, Ralf, Ludwig Kappos, Douglas L. Arnold, et al.. (2012). Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis. New England Journal of Medicine. 367(12). 1098–1107. 1318 indexed citations breakdown →
17.
Fox, Robert J., David H. Miller, J. Theodore Phillips, et al.. (2012). Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis. New England Journal of Medicine. 367(12). 1087–1097. 1036 indexed citations breakdown →
18.
19.
Vucic, Steve, et al.. (2007). Long-term effects of intravenous immunoglobulin in CIDP. Clinical Neurophysiology. 118(9). 1980–1984. 22 indexed citations
20.
Vucic, Steve, Peter Siao Tick Chong, Katherine Dawson, Merit Cudkowicz, & David Cros. (2004). Thromboembolic Complications of Intravenous Immunoglobulin Treatment. European Neurology. 52(3). 141–144. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gavin Giovannoni Breakdown of academic impact, for papers by P Burtin Breakdown of academic impact, for papers by Sarah Ryan Breakdown of academic impact, for papers by Roberto Piva Breakdown of academic impact, for papers by Serena Ruggieri Breakdown of academic impact, for papers by Chuanzhen Lü Breakdown of academic impact, for papers by Matthew D. Linnik Breakdown of academic impact, for papers by Daniel D. Buchanan Breakdown of academic impact, for papers by Yasuyuki Kihara Breakdown of academic impact, for papers by René Santer
Rankless by CCL
2026